Indi Molecular said this week that it has raised $300,000 from a new investor, Asset Management Ventures, bringing the total amount raised in its seed round to $1.8 million.

The company plans with this funding to continue development of its protein catalyzed capture reagents, a synthetic affinity agent technology that it hopes to position as an alternative to traditional antibodies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.